Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Queensland Health
Fish and Richardson
Healthtrust
US Department of Justice
Citi
Federal Trade Commission
AstraZeneca
Cantor Fitzgerald

Generated: April 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,500,867

« Back to Dashboard

Summary for Patent: 6,500,867
Title: Pharmaceutical composition comprising entacapone, levodopa, and carbidopa
Abstract:An oral solid fixed dose composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. The composition can be used, e.g., for the treatment of Parkinson's disease.
Inventor(s): Virkki; Matti (Masala, FI), Vahervuo; Kari (Espoo, FI), Ritala; Marja (Espoo, FI), Partanen; Marja (Espoo, FI), Niskanen; Mervi (Espoo, FI), Lintulaakso; Jarmo (Espoo, FI), Laaksonen; Marja (Masala, FI), Kervinen; Lasse (Helsinki, FI), Kallioinen; Sari (Espoo, FI)
Assignee: Orion Corporation (Espoo, FI)
Application Number:09/605,529
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation; Use; Process;

Drugs Protected by US Patent 6,500,867

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Orion Pharma STALEVO 100 carbidopa; entacapone; levodopa TABLET;ORAL 021485-002 Jun 11, 2003 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF PARKINSON'S DISEASE ➤ Try a Free Trial
Orion Pharma STALEVO 125 carbidopa; entacapone; levodopa TABLET;ORAL 021485-006 Aug 29, 2008 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF PARKINSON'S DISEASE ➤ Try a Free Trial
Orion Pharma STALEVO 150 carbidopa; entacapone; levodopa TABLET;ORAL 021485-003 Jun 11, 2003 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF PARKINSON'S DISEASE ➤ Try a Free Trial
Orion Pharma STALEVO 200 carbidopa; entacapone; levodopa TABLET;ORAL 021485-004 Aug 2, 2007 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y TREATMENT OF PARKINSON'S DISEASE ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,500,867

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Finland991485Jun 30, 1999

Non-Orange Book US Patents Family Members for Patent 6,500,867

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,797,732 Pharmaceutical composition comprising entracapone, levodopa, and carbidopa ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,500,867

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
China 1168440 ➤ Try a Free Trial
Colombia 5180579 ➤ Try a Free Trial
Austria 245417 ➤ Try a Free Trial
Czech Republic 20014636 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Citi
Boehringer Ingelheim
Accenture
Express Scripts
Julphar
Moodys
AstraZeneca
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.